Claims
- 1. A compound of the formula ##STR36## wherein X is CH.sub.2 ; Y is O, --CH.sub.2 --CH.sub.2 --, or --C.tbd.C--;
- Z is --CH.sub.2 --CH.sub.2 --; f and m are 1 and h, k, and t, independently, are 0 or 1;
- n is an integer from 1 to 12;
- R.sup.1 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, or aralkyl; and A is B or --O--B, wherein B is a mono-, di- or tricyclic aromatic moiety substituted by the group --COR.sup.2, --(O).sub.t --(W).sub.s --COR.sup.2 or --(CH.dbd.CH).sub.p COR.sup.2 and which may also contain up to 4 additional substituents selected, independently, from the group consisting of halogen, cyano, lower alkyl, lower alkoxy, sulfonamido, alkanoyl, aroyl, --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, provided that no more than one of said substituents is --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, and wherein E is COR.sup.2 or R.sup.2, W is --CR.sup.3 R.sup.4 --, Q is O or carbonyl, p is an integer from 1 to 2, s and s', independently, are an integer from 1-12, s" and s'", independently, are an integer from 0 to 12, C.sub.6 H.sub.4 is a 1,2-, 1,3-, or 1,4-phenylene moiety, and R.sup.2 is hydroxy, lower alkoxy or NR.sup.3 R.sup.4, wherein R.sup.3 and R.sup.4, each occurrence, independently, are hydrogen or lower alkyl,
- a geometric or optical isomer or, when R.sup.2 is hydroxy, a pharmaceutically acceptable salt thereof with a base.
- 2. A compound according to claim 1, wherein Y is O, R.sup.1 is lower alkyl and n is 3-8.
- 3. A compound according to claim 1, wherein Y is O, R.sup.1 is lower alkyl, h is O, n is 3-8, and A is B.
- 4. A compound according to claim 1, wherein Y is O, R.sup.1 is lower alkyl or aralkyl, h is O, n is 3-8 and A is B and B is a monocyclic aromatic moiety substituted by --(O).sub.t --(W).sub.s --COR.sup.2 and --(Q).sub.k --(W).sub.s' --E; wherein Q is O, R.sub.2 is hydroxy, t is O, s is 2, k is 1 and s' is 1 to 12.
- 5. A compound according to claim 1, which is 2-[(5-carboxypentyl)oxy]-6-[6-[5,6,7,8-tetrahydro-5-oxo-1-propyl-2-naphthalenyl)oxy]hexyl]benzenepropanoic acid.
- 6. A compound according to claim 1, wherein Y are O, R.sup.1 is lower alkyl, h is O, k are 1, n is 3-8 and A is B, and B is a monocyclic aromatic moiety substituted by --(O).sub.t --(W).sub.s --COR.sup.2 and --(Q).sub.k --(W).sub.s' --E, wherein Q is O, R.sub.2 is hydroxy, t is O, s is 2, and s' is 1 to 12.
- 7. A compound according to claim 6, wherein B is phenyl substituted by --(O).sub.t --(W).sub.s --COR.sup.2 and --(Q).sub.k --(W).sub.s' --COR.sup.2, wherein Q is O, R.sub.2 is hydroxy, t is O, s is 2, k is 1 and s' is 1-6.
- 8. A pharmaceutical composition which comprises an effective amount of a compound of formula I ##STR37## wherein X is CH.sub.2 ; Y is O, --CH.sub.2 --CH.sub.2 --, or --C.tbd.C--;
- Z is --CH.sub.2 --CH.sub.2 --; f and m are 1 and h, k, and t, independently, are 0 or 1;
- n is an integer from 1 to 12;
- R.sup.1 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, or aralkyl; and A is B or --O--B, wherein B is a mono-, di- or tricyclic aromatic moiety substituted by the group --COR.sup.2, --(O).sub.t --(W).sub.s --COR.sup.2 or --(CH.dbd.CH).sub.p COR.sup.2 and which may also contain up to 4 additional substituents selected, independently, from the group consisting of halogen, cyano, lower alkyl, lower alkoxy, sulfonamido, alkanoyl, aroyl, --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, provided that no more than one of said substituents is --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, and wherein E is COR.sup.2 or R.sup.2, W is --CR.sup.3 R.sup.4 --, Q is O or carbonyl, p is an integer from 1 to 2, s and s', independently, are an integer from 1-12, s" and s'", independently, are an integer from 0 to 12, C.sub.6 H.sub.4 is a 1,2-, 1,3-, or 1,4-phenylene moiety, and R.sup.2 is hydroxy, lower alkoxy or NR.sup.3 R.sup.4, wherein R.sup.3 and R.sup.4, each occurrence, independently, are hydrogen or lower alkyl,
- a geometric or optical isomer thereof, or when R.sup.2 is hydroxy, pharmaceutically acceptable salt thereof with a base, and an inert carrier.
- 9. A pharmaceutical composition according to claim 8, wherein Y is O, R.sup.1 is lower alkyl, n is 3-8.
- 10. A pharmaceutical composition according to claim 8, wherein Y is O, R.sup.1 is lower alkyl, h is O, n is 3-8, n is 1-8 an A is B.
- 11. A pharmaceutical composition according to claim 8, wherein Y is O, R.sup.1 is lower alkyl or aralkyl, h is O, n is 3-8 and A is B, and B is a monocyclic aromatic moiety substituted by --(O).sub.t --(W).sub.s --COR.sup.2 and --(Q).sub.k --(W).sub.s' --E; wherein Q is O, R.sub.2 is hydroxy, t is O, s is 2, k is 1 and s' is 1 to 12.
- 12. A pharmaceutical composition according to claim 7, wherein the compound of formula I is 2-[(5-carboxypentyl)oxy]-6-[6-[5,6,7,8-tetrahydro-5-oxo-1-propyl-2-naphthalenyl)oxy]hexyl]benzenepropanoic acid.
- 13. A method of inhibiting the biological activity of leukotriene B.sub.4 which comprises administering to a host requiring such inhibitory treatment an effective amount of a compound of formula I ##STR38## wherein X is CH.sub.2 ; Y is O, --CH.sub.2 --CH.sub.2 --, or --C.tbd.C--;
- Z is --CH.sub.2 --CH.sub.2 --; f and m are 1 and h, k, and t, independently, are 0 or 1;
- n is an integer from 1 to 12;
- R.sup.1 is hydrogen, lower alkyl, lower alkenyl, cycloalkyl, or aralkyl; and A is B or --O--B, wherein B is a mono-, di- or tricyclic aromatic moiety substituted by the group --COR.sup.2, --(O).sub.t --(W).sub.s --COR.sup.2 or --(CH.dbd.CH).sub.p COR.sup.2 and which may also contain up to 4 additional substituents selected, independently, from the group consisting of halogen, cyano, lower alkyl, lower alkoxy, sulfonamido, alkanoyl, aroyl, --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, provided that no more than one of said substituents is --(Q).sub.k --(W).sub.s' --E or --(Q).sub.k --(W).sub.s" --C.sub.6 H.sub.4 --(W).sub.s'" --E, and wherein E is COR.sup.2 or R.sup.2, W is --CR.sup.3 R.sup.4 --, Q is O or carbonyl, p is an integer from 1 to 2, s and s', independently, are an integer from 1-12, s" and s'", independently, are an integer from 0 to 12, C.sub.6 H.sub.4 is a 1,2-, 1,3-, or 1,4-phenylene moiety, and R.sup.2 is hydroxy, lower alkoxy or NR.sup.3 R.sup.4, wherein R.sup.3 and R.sup.4, each occurrence, independently, are hydrogen or lower alkyl,
- a geometric or optical isomer or, when R.sup.2 is hydroxy, a pharmaceutically acceptable salt thereof with a base.
- 14. A method according to claim 13, wherein Y is O, R.sup.1 is lower alkyl, h is O, n is 3-8, and A is B.
- 15. A method according to claim 13, wherein, Y is O, R.sup.1 is lower alkyl or aralkyl, h is O, n is 3-8 and A is B, and B is a monocyclic aromatic moiety substituted by --(O).sub.t --(W).sub.s --COR.sup.2 and --(Q).sub.k --(W).sub.s' --E, wherein Q is O, R.sub.2 is hydroxy, t is O, s is 2, k is 1 and s' is 1 to 12.
- 16. A method according to claim 13, wherein the compound of formula I is 2-[(5-carboxypentyl)oxy]-6-[6-[5,6,7,8-tetrahydro-5-oxo-1-propyl-2-naphthalenyl)oxy]hexyl]benzenepropanoic acid.
CROSS REFERENCE TO RELATED APPLICATION
This is a division of application Ser. No. 07/898,852, filed Jun. 15, 1992, now U.S. Pat. No. 5,273,999, which is a CIP of Ser. No. 07/757,100, filed Sep. 10, 1991 now abandoned.
US Referenced Citations (6)
Foreign Referenced Citations (4)
Number |
Date |
Country |
0079637 |
Nov 1982 |
EPX |
0292977 |
May 1988 |
EPX |
0405116A2 |
Jan 1991 |
EPX |
WO9200011 |
Sep 1992 |
WOX |
Non-Patent Literature Citations (4)
Entry |
Brown, F. J. et al.--Hydroxyacetophenone--Derived Antagonists of the Peptidoleukotrienes--J. Med. Chem. 1989, 32, 807-826. |
Gapinski, D. M. et al--Benzophenone Dicarboxylic Acid Antagonists of Leokotriene B.sub.4 --J. Med. Chem. 1990, 33, 2807-2873. |
Konno, M. et al--Synthesis and Structure--Activity Relationships of A Series of Substituted--Phenylpropionic Acids--Advanced in Prostaglandin Thromboxane and Leukotriene Res. vol. 21, 411-413 (1990). |
Communications-7-3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy-3,4-dihydro-8-propyl-2H-1-benzopyran-2-carboxylic acid--J. Med. Chem. 1989, vol. 32, No. 6, 1145-1147. |
Divisions (1)
|
Number |
Date |
Country |
Parent |
898852 |
Jun 1992 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
757100 |
Sep 1991 |
|